Completed PHASE2 INTERVENTIONAL 2-arm NCT00514943

BIBW 2992 (Afatinib) in Head & Neck Cancer

A Randomized, Open-label Phase II Study of BIBW 2992 Versus Cetuximab (Erbitux) in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy With a Cross-over Period for Progressing Patients

Sponsor: Boehringer Ingelheim

Conditions Carcinoma, Squamous Cell Head and Neck Neoplasms

Interventions BIBW 2992 Cetuximab

Updated 6 times since 2017 Last updated: Jun 24, 2016 Started: Aug 31, 2007 Primary completion: Mar 31, 2010 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00514943, this PHASE2 trial focuses on Carcinoma, Squamous Cell and Head and Neck Neoplasms and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alès, France , Ann Arbor, United States , Avignon, France , Baltimore, United States , Barcelona, Spain , Brussels, Belgium , Chapel Hill, United States , Charleston, United States , Chicago, United States , Ghent, Belgium and 23 more locations